www.fdanews.com/articles/126661-biocancell-receives-fda-approval-to-continue-bladder-cancer-trial

BioCancell Receives FDA Approval to Continue Bladder Cancer Trial

April 30, 2010

Tikcro Technologies announced that BioCancell Therapeutics concluded the first 18 patient group treated pursuant to a Phase IIb clinical trial of the drug candidate BC-819 for use in superficial bladder cancer.
MarketWatch